Study of LCAR-HL30 for Hodgkin's and anaplastic large cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called LCAR-HL30 for people with Hodgkin's lymphoma or anaplastic large cell lymphoma that has come back or not responded to therapy. The treatment targets cells with a protein called CD30 to help your body fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have Hodgkin's lymphoma or anaplastic large cell lymphoma with CD30 protein (confirmed by a lab test).
- Your cancer has come back after treatment or did not respond to previous therapy.
- You have at least one measurable tumor, and are expected to live at least 3 more months.
- You have not had certain prior treatments (like CAR-T therapy or a stem cell transplant from a donor) within a specific time.
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
This trial tests a new cell therapy (CD30 CAR T-cells) given after a stem cell transplant to treat Hodgkin lymphoma that has not responded well. It may help your body's immune cells fight the cancer more effectively.
This trial tests a new treatment that uses your own immune cells, modified to find and attack cancer cells that have a protein called CD30 on them. It may be an option if your lymphoma has come back or hasn't improved with other treatments.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Hear when a new Anaplastic Large Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.